Literature DB >> 16490435

Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes.

Aun Yeong Chong1, Bethan Freestone, Jeetesh Patel, Hoong Sern Lim, Elizabeth Hughes, Andrew D Blann, Gregory Y H Lip.   

Abstract

Congestive heart failure (CHF) is associated with marked endothelial dysfunction. We hypothesized that acute and chronic CHF may manifest different degrees of endothelial damage/dysfunction and activation, as reflected by different plasma endothelial markers, such as von Willebrand factor (vWF) and soluble thrombomodulin (both are indexes of endothelial damage/dysfunction) and soluble E-selectin (an index of endothelial activation). Second, we hypothesized a relation between endothelial markers and B-type natriuretic peptide (BNP, an index of cardiac function) in acute and chronic CHF that could be linked to prognosis. To test this hypothesis, we studied 35 patients with acute CHF, 40 patients with chronic CHF, and 32 healthy controls. The patients with CHF were followed up for the combined outcomes of cardiovascular death, nonfatal myocardial infarction, stroke, thromboembolism, and recurrent admissions to the hospital. vWF (p = 0.001), soluble thrombomodulin, E-selectin, and BNP (all p <0.0001) were higher in patients with acute and chronic CHF compared with controls. When the 2 CHF groups were compared, no significant differences were found in vWF or E-selectin (p = NS), but soluble thrombomodulin was significantly elevated in acute CHF (Tukey's post hoc test, p <0.05). Only high vWF was associated with a poorer outcome (log-rank test, p = 0.0188). None of the endothelial indexes correlated with plasma BNP. After a median follow-up of 18 months, only high (median or higher) vWF levels were predictive of adverse outcomes in the patients with CHF (log-rank statistic = 5.52, degree of freedom 1, p = 0.0188). In conclusion, despite similar ejection fractions, patients with acute and chronic CHF have different degrees of endothelial damage/dysfunction and activation, which may be related to differences in pathophysiology. High levels of vWF were associated with a worse short-term outcome. These endothelial markers were unrelated to plasma BNP levels and may imply a different release mechanism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490435     DOI: 10.1016/j.amjcard.2005.09.113

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

1.  Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function: the MESA-RV Study.

Authors:  Steven M Kawut; R Graham Barr; W Craig Johnson; Harjit Chahal; Harikrishna Tandri; Aditya Jain; Michael R Bristow; Jorge R Kizer; Emilia Bagiella; Joao A C Lima; David A Bluemke
Journal:  Biomarkers       Date:  2010-10-05       Impact factor: 2.658

2.  The effect of preoperative aspirin administration on postoperative level of von Willebrand factor in off-pump coronary artery bypass surgery.

Authors:  Kaoru Matsuura; Mizuho Imamaki; Atsushi Ishida; Hitoshi Shimura; Masaru Miyazaki
Journal:  Heart Vessels       Date:  2009-05-24       Impact factor: 2.037

3.  Von Willebrand factor and the right ventricle (the MESA-Right Ventricle Study).

Authors:  Peter J Leary; R Graham Barr; David A Bluemke; Michael R Bristow; Catherine L Hough; Richard A Kronmal; Joao A Lima; Robyn L McClelland; Russell P Tracy; Steven M Kawut
Journal:  Am J Cardiol       Date:  2012-09-18       Impact factor: 2.778

4.  Serum soluble E-selectin and NT-proBNP levels additively predict mortality in diabetic patients with chronic heart failure.

Authors:  Judit Czúcz; László Cervenak; Zsolt Förhécz; Tímea Gombos; Zoltán Pozsonyi; Jan Kunde; István Karádi; Lívia Jánoskuti; Zoltán Prohászka
Journal:  Clin Res Cardiol       Date:  2011-02-11       Impact factor: 5.460

5.  Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction.

Authors:  Robin A P Weir; Sean Balmain; Tracey Steedman; Leong L Ng; Iain B Squire; Anne Rumley; Henry J Dargie; Gordon D O Lowe
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

Review 6.  Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review.

Authors:  David R Buvat de Virginy
Journal:  Heart Fail Rev       Date:  2006-12       Impact factor: 4.214

Review 7.  Safety and efficacy of new anticoagulants in patients with heart failure.

Authors:  Ron Pisters; Gregory Y H Lip
Journal:  Curr Heart Fail Rep       Date:  2013-03

8.  Fenofibrate Modulates HO-1 and Ameliorates Endothelial Expression of Cell Adhesion Molecules in Systolic Heart Failure.

Authors:  Wei-Hsian Yin; Jaw-Wen Chen; Yung-Hsiang Chen; Shing-Jong Lin
Journal:  Acta Cardiol Sin       Date:  2013-05       Impact factor: 2.672

9.  Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure.

Authors:  Tom D J Smilde; Kevin Damman; Pim van der Harst; Gerjan Navis; B Daan Westenbrink; Adriaan A Voors; Frans Boomsma; Dirk J van Veldhuisen; Hans L Hillege
Journal:  Clin Res Cardiol       Date:  2008-10-31       Impact factor: 5.460

10.  Intra-renal delivery of mesenchymal stem cells attenuates myocardial injury after reversal of hypertension in porcine renovascular disease.

Authors:  Alfonso Eirin; Xiang-Yang Zhu; Christopher M Ferguson; Scott M Riester; Andre J van Wijnen; Amir Lerman; Lilach O Lerman
Journal:  Stem Cell Res Ther       Date:  2015-01-19       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.